Mycophenolate Mofetil Hydrochloride · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil Hydrochloride (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental application (ANDA204043) for mycophenolate mofetil hydrochloride injectable formulation (500 mg/vial) under Risk Evaluation and Mitigation Strategy (REMS) requirements on 29 July 2026. This is a regulatory action record that does not contain clinical trial results or efficacy and safety data.

What was studied

Regulatory label update.

Key findings

Supplemental approval granted for mycophenolate mofetil hydrochloride injectable, 500 mg/vial formulation Approval subject to REMS (Risk Evaluation and Mitigation Strategy) requirements Approval date: 29 July 2026

Safety

This record does not contain clinical trial results, efficacy data, or safety outcomes. Approval status alone does not indicate clinical benefit or adverse event profile; underlying clinical data not provided in this record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of mycophenolate mofetil hydrochloride injectable formulation under REMS requirements; regulatory action without clinical trial outcome data.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-07-29

Product strength500 mg/vial

Caveats

This record does not contain clinical trial results, efficacy data, or safety outcomes.
REMS requirements are mandated but specific elements are not detailed in this approval notice.
No comparative efficacy or head-to-head trial data reported.
Approval status alone does not indicate clinical benefit or adverse event profile; underlying clinical data not provided in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory approval record; no clinical study design reported.

Directness

insufficient

Regulatory action record contains no clinical efficacy or safety trial data.

Consistency

insufficient

Single regulatory action; no comparative or confirmatory trial data provided.

Risk of bias

insufficient

Not applicable to regulatory approval record without underlying clinical trial reporting.

Sample adequacy

insufficient

Regulatory record does not report sample size or trial population data.

Source abstract

Drugs@FDA record for application ANDA204043. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL HYDROCHLORIDE. Active ingredient: MYCOPHENOLATE MOFETIL HYDROCHLORIDE. Sponsor: RISING. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL HYDROCHLORIDE, INJECTABLE, INJECTION, MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIAL.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

RisingMycophenolate Mofetil Hydrochloride